Loading...
XNAS
HROWM
Market cap1.14bUSD
Jun 23, Last price  
26.50USD
1D
0.26%
1Q
-1.49%
IPO
7.20%
Name

Harrow Health Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.00
EPS
—
Div Yield, %
8.40%
Shrs. gr., 5y
6.14%
Rev. gr., 5y
1,980.86%
Revenues
199.61t
+153,321,507.15%
000000100,00010,0001,660,2469,716,00019,942,00026,774,00041,372,00051,165,00048,871,00072,476,00088,595,000130,193,000199,614,000,000,000
Net income
-17m
L-28.39%
-46,206-4,284,540-3,304,388-4,553,636-2,531,228-953,936-5,383,535-7,643,124-10,118,103-15,899,000-19,087,000-11,985,00014,625,000-2,592,000-3,419,000-18,007,000-14,086,000-24,411,000-17,481,000
CFO
-22m
L
-40,056-1,763,621-2,533,485-3,570,758-2,298,311-291,160-1,900,840-4,438,944-7,055,428-11,143,000-11,215,000-8,803,000687,000950,000-1,100,0005,082,0001,705,0003,840,000-22,202,000
Dividend
Jul 15, 20240.74219 USD/sh
Earnings
Aug 05, 2025

Profile

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
URL
https://www.harrowinc.com/
IPO date
Feb 08, 2013
Employees
217
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
199,614,000,000
153,321,507.15%
130,193
46.95%
88,595
22.24%
Cost of revenue
61,475,000,000
46,523
28,433
Unusual Expense (Income)
NOPBT
138,139,000,000
83,670
60,162
NOPBT Margin
69.20%
64.27%
67.91%
Operating Taxes
(161,000,000)
470
75
Tax Rate
0.56%
0.12%
NOPAT
138,300,000,000
83,200
60,087
Net income
(17,481)
-28.39%
(24,411)
73.30%
(14,086)
-21.77%
Dividends
Dividend yield
Proceeds from repurchase of equity
64,520
21,779
BB yield
-17.66%
-5.37%
Debt
Debt current
497
806
723
Long-term debt
237,620
197,026
112,229
Deferred revenue
Other long-term liabilities
228,330,771,669
2,713
7,332
Net debt
(47,246,761,883)
115,066
16,682
Cash flow
Cash from operating activities
(22,202)
3,840
1,705
CAPEX
(1,595,000,000)
(1,460)
(7,773)
Cash from investing activities
(33,164,000,000)
(152,553)
(1,743)
Cash from financing activities
28,528,000,000
126,528
54,141
FCF
76,537,016,401
92,725
41,704
Balance
Cash
47,247,000,000
82,766
96,270
Long term investments
Excess cash
37,266,300,000
76,256
91,840
Stockholders' equity
(151,739,999,965)
(134,224)
(109,818)
Invested Capital
449,368,000,462
397,850
248,932
ROIC
61.55%
25.73%
27.72%
ROCE
46.41%
31.74%
43.25%
EV
Common stock shares outstanding
35,651
32,617
27,461
Price
33.55
199.55%
11.20
-24.12%
14.76
70.83%
Market cap
1,196,081
227.42%
365,308
-9.87%
405,324
75.32%
EV
(47,600,565,802)
480,019
421,651
EBITDA
138,139,014,537
96,010
63,827
EV/EBITDA
5.00
6.61
Interest
22,786
21,324
7,244
Interest/NOPBT
0.00%
25.49%
12.04%